RATIONALE: Paroxetine may decrease mental stress-induced cardiovascular responses and so benefit individuals with heart disease, even those with no psychiatric illness. OBJECTIVES: The effects of paroxetine on cardiovascular measures during a speech task were evaluated in psychiatrically healthy subjects with a history of coronary artery disease (CAD). METHODS: Eight subjects completed this double-blind, placebo-controlled, cross-over study in which each subject took 1 month of paroxetine and 4 weeks of placebo in random order. While on each study, medication, blood pressure, heart rate, and plasma norepinephrine concentrations were measured during a period of relaxation and during a mental stressor. The mental stressor consisted of thinking about a stressful topic, speaking about the topic, and listening to a tape-recorded replay of the speech. RESULTS: While on paroxetine, systolic blood pressure and diastolic blood pressure were 10-15% lower (p < 0.005) during the stressor, relative to measures obtained while on placebo. Pulse and plasma norepinephrine concentrations during stress trended lower during paroxetine treatment but did not reach statistical significance. CONCLUSION:Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities.
RCT Entities:
RATIONALE: Paroxetine may decrease mental stress-induced cardiovascular responses and so benefit individuals with heart disease, even those with no psychiatric illness. OBJECTIVES: The effects of paroxetine on cardiovascular measures during a speech task were evaluated in psychiatrically healthy subjects with a history of coronary artery disease (CAD). METHODS: Eight subjects completed this double-blind, placebo-controlled, cross-over study in which each subject took 1 month of paroxetine and 4 weeks of placebo in random order. While on each study, medication, blood pressure, heart rate, and plasma norepinephrine concentrations were measured during a period of relaxation and during a mental stressor. The mental stressor consisted of thinking about a stressful topic, speaking about the topic, and listening to a tape-recorded replay of the speech. RESULTS: While on paroxetine, systolic blood pressure and diastolic blood pressure were 10-15% lower (p < 0.005) during the stressor, relative to measures obtained while on placebo. Pulse and plasma norepinephrine concentrations during stress trended lower during paroxetine treatment but did not reach statistical significance. CONCLUSION:Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities.
Authors: J D Amsterdam; F Garcia-Espana; J Fawcett; F M Quitkin; F W Reimherr; J F Rosenbaum; C Beasley Journal: J Clin Psychopharmacol Date: 1999-02 Impact factor: 3.153
Authors: David S Sheps; Robert P McMahon; Lewis Becker; Robert M Carney; Kenneth E Freedland; Jerome D Cohen; David Sheffield; A David Goldberg; Mark W Ketterer; Carl J Pepine; James M Raczynski; Kathleen Light; David S Krantz; Peter H Stone; Genell L Knatterud; Peter G Kaufmann Journal: Circulation Date: 2002-04-16 Impact factor: 29.690
Authors: W Jiang; M Babyak; D S Krantz; R A Waugh; R E Coleman; M M Hanson; D J Frid; S McNulty; J J Morris; C M O'Connor; J A Blumenthal Journal: JAMA Date: 1996-06-05 Impact factor: 56.272
Authors: Michael Kotlyar; Mustafa al'Absi; Paul Thuras; John P Vuchetich; David E Adson; April L Nowack; Dorothy K Hatsukami Journal: Psychosom Med Date: 2013-03-15 Impact factor: 4.312
Authors: Wei Jiang; Eric J Velazquez; Maragatha Kuchibhatla; Zainab Samad; Stephen H Boyle; Cynthia Kuhn; Richard C Becker; Thomas L Ortel; Redford B Williams; Joseph G Rogers; Christopher O'Connor Journal: JAMA Date: 2013-05-22 Impact factor: 56.272
Authors: Sarah Kim; Gezim Lahu; Majid Vakilynejad; Theodoros G Soldatos; David B Jackson; Lawrence J Lesko; Mirjam N Trame Journal: Clin Transl Sci Date: 2022-01-11 Impact factor: 4.438